Iambic Therapeutics, Inc. (IAM) insider trading
Iambic Therapeutics, Inc. insiders have made 1 open-market purchase worth $11.5M since Oct 19, 2026, by 1 insider. The latest: Evan Lockwood Rachlin (Director) bought $11.5M, filed Oct 19, 2026, scored 46 out of 100.
Follow IAM, freeOpen the live feed
A free account gets an alert the minute a new buy or sale is filed.
Insider purchases
| Filed | Insider | Stake | Score | Bought | 1 week | 1 month |
|---|---|---|---|---|---|---|
| Oct 19 Form 4 (opens sec.gov) |
Evan Lockwood RachlinDirectorDirector | +38% stake | 46 | $11.5M 718,750 at $16.00 |
−12.6% | waiting |
Track record (hypothetical): a week after the filing, these buys averaged −12.6% (0% up, 1 measured).
Insiders who bought IAM
- Evan Lockwood Rachlin Director
Questions
Are insiders buying IAM stock?
Yes. In the last 90 days, 1 open-market purchase was filed, worth $11.5M.
Who bought IAM stock most recently?
Evan Lockwood Rachlin, Director, bought 718,750 shares for $11.5M (Form 4 (opens sec.gov), filed Oct 19, 2026).
How does InsiderBeacon score an insider buy?
Out of 100, from who bought, how much their stake grew, the size of the trade, whether other insiders bought within ten days, where the price sat in its 52-week range, and whether it was a first or a routine buy. The score is fixed when the filing arrives. The formula and the research behind it.
Insiders are also buying, same industry
Data as of Oct 19, 2026, from SEC EDGAR Form 4 filings: open-market purchases (code P) of $25,000 or more, and open-market sales. Every row links to its filing. Scores summarise what a filing says (how the score works); outcomes are hypothetical, from the first close after the filing, and past results don't predict future ones. Disclaimer